Cochrane · systematic review · CD010969
Harms of off‐label erythropoiesis‐stimulating agents for critically ill people
Mesgarpour, B, Heidinger, BH, Roth, D, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Emergency and Critical CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: Critically‐ill people
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Any adverse event | RR 1.05 [0.93, 1.21] | 8 studies · 3099 participants | Low Downgraded: risk of bias, imprecision |
Venous thromboembolism | RR 1.04 [0.7, 1.41] | 13 studies · 18917 participants | Very low Downgraded: risk of bias, inconsistency |
Mortality | RR 0.76 [0.61, 0.92] | 25 studies · 930470 participants | Low Downgraded: risk of bias, inconsistency |